17 Apr 2012 07:00

FOR IMMEDIATE RELEASE | 17 April 2012 |
Â
Â
ImmuPharma plc
Â
Annual Report and Accounts
Â
Notice of Annual General Meeting: 23 May 2012
Â
Â
In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM: IMM) (the "Company") the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2011 has been posted to shareholders.
Â
The annual report is available, in electronic form, for download on the Company's website www.immupharma.com.
Â
The Company's Annual General Meeting will be held on 23 May 2012 at 11:00am at the offices of Bircham Dyson Bell LLP, 50 Broadway, London SW1H 0BL.
Â
Â
- Ends -
Â
Â
Â
For further information please contact:
Â
ImmuPharma plc | + 44 (0) 20 7152 4080 |
Dimitri Dimitriou, Chief Executive Officer | |
Lisa Baderoon, Head of Investor Relations | + 44 (0) 7721 413496 |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court | |
Jessica Fontaine | |
Panmure, Gordon & Co., NOMAD & Broker | +44 (0) 20 7459 3600 |
Andrew Burnett | |
Fred Walsh | |
Espirito Santo Investment Bank | +44 (0) 20 7456 9191 |
James Bromhead | |
Richard Crawley |
Â